Press Releases
Alkeus Announces $150 Million Series B Financing, Supporting Rapid Registration Path for gildeuretinol (ALK-001) in the Treatment of Stargardt Disease
June 5, 2023
Alkeus Pharmaceuticals to Present at the 4th Annual Evercore ISI HealthCONx Conference
November 29, 2021
FDA Grants Alkeus Pharmaceuticals Breakthrough Therapy Designation for ALK-001 (C20-D3-vitamin A) for the Treatment of Stargardt Disease
July 14, 2021